{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:02:24Z","timestamp":1787749344615,"version":"build-2784847793"},"reference-count":79,"publisher":"Elsevier","isbn-type":[{"value":"9780443429835","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031160","name":"Cartesian Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031160","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003157","name":"Myasthenia Gravis Foundation of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003157","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.irn.2025.04.031","type":"book-chapter","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T08:33:19Z","timestamp":1753259599000},"page":"21-42","source":"Crossref","is-referenced-by-count":4,"title":["Neuromuscular junction and the complement system"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.irn.2025.04.031_bib1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ensci.2019.01.006","article-title":"Eculizumab improved weakness and taste disorder in thymoma-associated generalized myasthenia gravis with anti-striational antibodies: A case report","volume":"14","author":"Amano","year":"2019","journal-title":"eNeurologicalSci"},{"issue":"8","key":"10.1016\/bs.irn.2025.04.031_bib2","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.4049\/jimmunol.142.8.2654","article-title":"Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6","volume":"142","author":"Biesecker","year":"1989","journal-title":"Journal of Immunology"},{"issue":"4-5","key":"10.1016\/bs.irn.2025.04.031_bib3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1078\/0171-2985-00141","article-title":"C1q, autoimmunity and apoptosis","volume":"205","author":"Botto","year":"2002","journal-title":"Immunobiology"},{"key":"10.1016\/bs.irn.2025.04.031_bib4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.pediatrneurol.2024.04.020","article-title":"Eculizumab in adolescent patients with refractory generalized myasthenia gravis: A phase 3, open-label, multicenter study","volume":"156","author":"Brandsema","year":"2024","journal-title":"Pediatric Neurology"},{"issue":"7981","key":"10.1016\/bs.irn.2025.04.031_bib5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0140-6736(76)92644-1","article-title":"Letter: Immune complexes in myasthenia gravis","volume":"2","author":"Casali","year":"1976","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.031_bib6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2249.2006.03198.x","article-title":"Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats","volume":"146","author":"Chamberlain-Banoub","year":"2006","journal-title":"Clinical and Experimental Immunology"},{"issue":"8","key":"10.1016\/bs.irn.2025.04.031_bib7","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.4049\/jimmunol.140.8.2589","article-title":"C5 gene influences the development of murine myasthenia gravis","volume":"140","author":"Christadoss","year":"1988","journal-title":"Journal of Immunology"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.031_bib8","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/1744666X.2022.2082946","article-title":"Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis","volume":"18","author":"Dalakas","year":"2022","journal-title":"Expert Review of Clinical Immunology"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.031_bib9","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","article-title":"Complement in neurological disorders and emerging complement-targeted therapeutics","volume":"16","author":"Dalakas","year":"2020","journal-title":"Nature Reviews. Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.031_bib10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3233\/JND-190464","article-title":"Retrospective analysis of eculizumab in patients with acetylcholine receptor antibody-negative myasthenia gravis: A case series","volume":"7","author":"Datta","year":"2020","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.031_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269749","article-title":"Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates","volume":"17","author":"Devalaraja-Narashimha","year":"2022","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.031_bib12","first-page":"267","article-title":"Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: Ultrastructural and light microscopic localization and electrophysiologic correlations","volume":"52","author":"Engel","year":"1977","journal-title":"Mayo Clinic Proceedings"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.031_bib13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1212\/WNL.29.2.179","article-title":"Passively transferredexperimental autoimmune myasthenia gravis. Sequential and quantitative study ofthe motor end-plate fine structure and ultrastructural localization of immunecomplexes (IgG and C3), and of the acetylcholine receptor","volume":"29","author":"Engel","year":"1979","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.031_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264489","article-title":"Myasthenia gravis complement activity is independent of autoantibody titer and disease severity","volume":"17","author":"Fichtner","year":"2022","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.031_bib15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nature Reviews. Disease Primers"},{"issue":"9","key":"10.1016\/bs.irn.2025.04.031_bib16","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.4049\/jimmunol.150.9.4093","article-title":"Age-related resistance to experimental autoimmune myasthenia gravis in rats","volume":"150","author":"Graus","year":"1993","journal-title":"Journal of Immunology"},{"key":"10.1016\/bs.irn.2025.04.031_bib17","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.921431","article-title":"Successful transition from plasma exchange to eculizumab in acetylcholine receptor antibody- and muscle-specific kinase (MuSK) antibody-negative myasthenia gravis: A case report","volume":"21","author":"Greenwood","year":"2020","journal-title":"The American Journal of Case Reports"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.031_bib18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molimm.2007.06.144","article-title":"Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivo","volume":"45","author":"Hepburn","year":"2008","journal-title":"Molecular Immunology"},{"issue":"9","key":"10.1016\/bs.irn.2025.04.031_bib19","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1007\/s00415-021-10428-6","article-title":"Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19","volume":"268","author":"Hofstadt-van Oy","year":"2021","journal-title":"Journal of Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.031_bib20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle & Nerve"},{"issue":"12","key":"10.1016\/bs.irn.2025.04.031_bib21","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.031_bib22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/13543784.2021.1897567","article-title":"Zilucoplan: An investigational complement C5 Inhibitor for the treatment of acetylcholine receptor autoantibody-positive generalized myasthenia gravis","volume":"30","author":"Howard","year":"2021","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.031_bib23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: The role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.031_bib24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"RAISE Study Team. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.irn.2025.04.031_bib25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaut.2013.01.003","article-title":"Complement C2 siRNA mediated therapy of myasthenia gravis in mice","volume":"42","author":"Huda","year":"2013","journal-title":"Journal of Autoimmunity"},{"issue":"8","key":"10.1016\/bs.irn.2025.04.031_bib26","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archneurol.2012.437","article-title":"Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis","volume":"69","author":"Jacob","year":"2012","journal-title":"Archives of Neurology"},{"key":"10.1016\/bs.irn.2025.04.031_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420911784","article-title":"Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: A subgroup analysis of REGAIN and its open-label extension study","volume":"13","author":"Jacob","year":"2020","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.031_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.expneurol.2004.06.005","article-title":"Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis","volume":"189","author":"Kaminski","year":"2004","journal-title":"Experimental Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.031_bib29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.expneurol.2006.06.003","article-title":"Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia","volume":"202","author":"Kaminski","year":"2006","journal-title":"Experimental Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.031_bib30","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3233\/JND-200584","article-title":"Clinical experience with eculizumab in treatment-refractory acetylcholine receptor antibody-positive generalized myasthenia gravis","volume":"8","author":"Katyal","year":"2021","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.031_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nri1994","article-title":"T-cell regulation: With complements from innate immunity","volume":"7","author":"Kemper","year":"2007","journal-title":"Nature Reviews. Immunology"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.031_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cells8070671","article-title":"Myasthenia gravis: Pathogenic effects of autoantibodies on neuromuscular architecture","volume":"8","author":"Koneczny","year":"2019","journal-title":"Cells"},{"key":"10.1016\/bs.irn.2025.04.031_bib33","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.omtm.2019.04.009","article-title":"Investigational RNAi therapeutic targeting C5 is efficacious in pre-clinical models of myasthenia gravis","volume":"13","author":"Kusner","year":"2019","journal-title":"Molecular Therapy. Methods & Clinical Development"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.031_bib34","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/mus.24057","article-title":"Targeting therapy to the neuromuscular junction: Proof of concept","volume":"49","author":"Kusner","year":"2014","journal-title":"Muscle & Nerve"},{"issue":"15","key":"10.1016\/bs.irn.2025.04.031_bib35","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/bloodadvances.2020002497","article-title":"Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients","volume":"4","author":"Langereis","year":"2020","journal-title":"Blood Advances"},{"key":"10.1016\/bs.irn.2025.04.031_bib36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.031_bib37","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1084\/jem.147.4.973","article-title":"Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis","volume":"147","author":"Lennon","year":"1978","journal-title":"The Journal of Experimental Medicine"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.031_bib38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jneuroim.2008.12.013","article-title":"Mannose-binding lectin pathway is not involved in myasthenia gravis pathogenesis","volume":"208","author":"Li","year":"2009","journal-title":"Journal of Neuroimmunology"},{"issue":"9","key":"10.1016\/bs.irn.2025.04.031_bib39","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1172\/JCI0216086","article-title":"Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection","volume":"110","author":"Lin","year":"2002","journal-title":"The Journal of Clinical Investigation"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.031_bib40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1046\/j.1365-2567.2001.01287.x","article-title":"Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies","volume":"104","author":"Lin","year":"2001","journal-title":"Immunology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.031_bib41","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/mus.21398","article-title":"Correlation of C3 level with severity of generalized myasthenia gravis","volume":"40","author":"Liu","year":"2009","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.031_bib42","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology--mode of action and clinical efficacy","volume":"11","author":"Lunemann","year":"2015","journal-title":"Nature Reviews. Neurology"},{"issue":"9","key":"10.1016\/bs.irn.2025.04.031_bib43","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/14712598.2020.1786530","article-title":"Eculizumab for the treatment of myasthenia gravis","volume":"20","author":"Mantegazza","year":"2020","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1016\/bs.irn.2025.04.031_bib44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/ITT.S261414","article-title":"Complement Inhibition for the treatment of myasthenia gravis","volume":"9","author":"Mantegazza","year":"2020","journal-title":"Immuno Targets and Therapy"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.031_bib45","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1212\/WNL.0000000000011207","article-title":"Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during regain and its open-label extension","volume":"96","author":"Mantegazza","year":"2021","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.031_bib46","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-019-01068-2","article-title":"Ravulizumab: First global approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.031_bib47","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","article-title":"The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice","volume":"146","author":"Morgan","year":"2006","journal-title":"Clinical and Experimental Immunology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.031_bib48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle & Nerve"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.031_bib49","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1212\/WNL.43.6.1167","article-title":"Myasthenia gravis: Quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients","volume":"43","author":"Nakano","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.031_bib50","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3181\/00379727-105-26050","article-title":"Changes in serum complement activity in patients with myasthenia gravis","volume":"105","author":"Nastuk","year":"1960","journal-title":"Proceedings of the Society for Experimental Biology and Medicine"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.031_bib51","article-title":"Heterogeneity of acetylcholine receptor autoantibody-mediated complement activity in patients with myasthenia gravis","volume":"9","author":"Obaid","year":"2022","journal-title":"Neurology\u00ae Neuroimmunology & Neuroinflammation"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.031_bib52","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/ene.14500","article-title":"Changes in serum complements and their regulators in generalized myasthenia gravis","volume":"28","author":"Ozawa","year":"2021","journal-title":"European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies"},{"key":"10.1016\/bs.irn.2025.04.031_bib53","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8206.1","article-title":"Pathogenesis of myasthenia gravis: Update on disease types, models, and mechanisms","volume":"5","author":"Phillips","year":"2016","journal-title":"F1000Research"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.031_bib54","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0165-5728(96)00144-0","article-title":"Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis","volume":"71","author":"Piddlesden","year":"1996","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2025.04.031_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneumeth.2022.109551","article-title":"A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies","volume":"373","author":"Plomp","year":"2022","journal-title":"Journal of Neuroscience Methods"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.031_bib56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jneuroim.2008.03.007","article-title":"C5a is not involved in experimental autoimmune myasthenia gravis pathogenesis","volume":"196","author":"Qi","year":"2008","journal-title":"Journal of Neuroimmunology"},{"issue":"12","key":"10.1016\/bs.irn.2025.04.031_bib57","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1073\/pnas.73.12.4584","article-title":"Studies of human myasthenia gravis: Electrophysiological and ultrastructural evidence compatible with antibody attachment to acetylcholine receptor complex","volume":"73","author":"Rash","year":"1976","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.031_bib58","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jneuroim.2004.08.002","article-title":"The role of complement in myasthenia gravis: Serological evidence of complement consumption in vivo","volume":"158","author":"Romi","year":"2005","journal-title":"Journal of Neuroimmunology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.031_bib59","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ncl.2018.01.001","article-title":"Nature and action of antibodies in myasthenia gravis","volume":"36","author":"Ruff","year":"2018","journal-title":"Neurologic Clinics"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.031_bib60","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00005072-197803000-00008","article-title":"Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis","volume":"37","author":"Sahashi","year":"1978","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.031_bib61","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00005072-198003000-00005","article-title":"Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis","volume":"39","author":"Sahashi","year":"1980","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.031_bib62","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ana.20341","article-title":"Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis","volume":"57","author":"Shiraishi","year":"2005","journal-title":"Annals of Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.031_bib63","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/mus.27422","article-title":"Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: Subgroup analysis of REGAIN and its extension study","volume":"64","author":"Siddiqi","year":"2021","journal-title":"Muscle & Nerve"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.031_bib64","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1476-9255-9-20","article-title":"Complement regulatory protein Crry deficiency contributes to the antigen specific recall response in experimental autoimmune myasthenia gravis","volume":"9","author":"Soltys","year":"2012","journal-title":"Journal of Inflammation"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.031_bib65","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ana.21536","article-title":"Novel complement inhibitor limits severity of experimentally myasthenia gravis","volume":"65","author":"Soltys","year":"2009","journal-title":"Annals of Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.031_bib66","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/ene.15730","article-title":"Complement activation profiles in anti-acetylcholine receptor positive myasthenia gravis","volume":"30","author":"Stascheit","year":"2023","journal-title":"European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.031_bib67","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3181\/00379727-105-26051","article-title":"Immunofluorescence demonstration of a muscle binding, complement-fixing serum globulin fraction in myasthenia gravis","volume":"105","author":"Strauss","year":"1960","journal-title":"Proceedings of the Society for Experimental Biology and Medicine"},{"key":"10.1016\/bs.irn.2025.04.031_bib68","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fnmol.2020.00086","article-title":"Myasthenia gravis: From the viewpoint of pathogenicity focusing on acetylcholine receptor clustering, trans-synaptic homeostasis and synaptic stability","volume":"13","author":"Takamori","year":"2020","journal-title":"Frontiers in Molecular Neuroscience"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.031_bib69","doi-asserted-by":"crossref","first-page":"119","DOI":"10.18553\/jmcp.2022.28.1.119","article-title":"The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis","volume":"28","author":"Tice","year":"2022","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.031_bib70","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jneuroim.2006.07.016","article-title":"Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis","volume":"181","author":"Tuzun","year":"2006","journal-title":"Journal of Neuroimmunology"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.031_bib71","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.4049\/jimmunol.171.7.3847","article-title":"Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis","volume":"171","author":"Tuzun","year":"2003","journal-title":"Journal of Immunology"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.031_bib72","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jneuroim.2006.10.014","article-title":"Pros and cons of treating murine myasthenia gravis with anti-C1q antibody","volume":"182","author":"Tuzun","year":"2007","journal-title":"Journal of Neuroimmunology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.031_bib73","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mus.27326","article-title":"The use of eculizumab in ventilator-dependent myasthenia gravis patients","volume":"64","author":"Usman","year":"2021","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.031_bib74","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420932035","article-title":"Eculizumab as a promising treatment in thymoma-associated myasthenia gravis","volume":"13","author":"Velez-Santamaria","year":"2020","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.031_bib75","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","article-title":"Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab","volume":"267","author":"Vissing","year":"2020","journal-title":"Journal of Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.031_bib76","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evidence"},{"issue":"ement 1","key":"10.1016\/bs.irn.2025.04.031_bib77","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2018-99-112262","article-title":"A randomized, double-blind, placebo-controlled phase 1 study of the pharmacokinetics and pharmacodynamics of REGN3918, a human antibody against complement factor C5, in healthy volunteers","volume":"132","author":"Weyne","year":"2018","journal-title":"Blood"},{"key":"10.1016\/bs.irn.2025.04.031_bib78","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.molimm.2019.07.030","article-title":"Compendium of current complement therapeutics","volume":"114","author":"Zelek","year":"2019","journal-title":"Molecular Immunology"},{"issue":"12","key":"10.1016\/bs.irn.2025.04.031_bib79","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.4049\/jimmunol.179.12.8562","article-title":"Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis","volume":"179","author":"Zhou","year":"2007","journal-title":"Journal of Immunology"}],"container-title":["International Review of Neurobiology","Myasthenia Gravis: Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774225000467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774225000467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:20:56Z","timestamp":1762230056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774225000467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443429835"],"references-count":79,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2025.04.031","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}